The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations.
To assess whether immune globulin may be administered concurrently with trivalent oral poliovirus vaccine (OPV) or yellow fever vaccine, antibody responses were studied in Peace Corps volunteers embarking for overseas duty in 1978. Of 200 volunteers who received OPV, 192 (96%) had pre-existing neutralizing antibody to at least 2 poliovirus types; of 160 yellow fever vaccinees, 24 (15%) had pre-existing 17D yellow fever antibody. Each volunteer received 5 ml of immune globulin, 0-7 days before, 3-5 days after, or 28-32 days after vaccination. This last group was designated the control group. Of the volunteers who received immune globulin 0-7 days before vaccination, 71% 72%, 49%, and 82% responded to poliovirus types 1, 2, and 3, and yellow fever, respectively (response was defined as a 4-fold or greater rise in serum neutralizing antibody titre between baseline (0-7 days before vaccination) and follow-up (15-40 days after vaccination)). These rates did not differ significantly from those in persons who received immune globulin 28-32 days after vaccination (61%, 60%, 51%, and 83%, respectively). Thus, among individuals who, for the most part, were immune to poliomyelitis but not to yellow fever, immune globulin did not decrease the antibody response to OPV or to yellow fever vaccine when given 0-7 days before vaccination.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015004:Yellow Fever / Q000276:immunology*
D000914:Antibodies, Viral; D007136:Immunoglobulins; D011054:Poliovirus Vaccine, Inactivated; D014765:Viral Vaccines